EUVIMEDEUVIMED entdecken
Crossref

Tisotumab Vedotin (Tivdak) for Cervical Cancer

The Medical Letter on Drugs and Therapeutics · 24.06.2024 · 66 (1705) · e109-e110

DOI: 10.58347/tml.2024.1705g ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 24.06.2024. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tisotumab vedotin-tftv (Tivdak – Seagen/Genmab), a tissue factor-directed antibody and microtubule inhibitor conjugate, has received full approval from the FDA for treatment of recurrent or metastatic cervical cancer that progressed on or after chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsHumansFemaleAntibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunological

Stichwörter der Autor:innen

Tivdakadverse effectscervical cancerdosagedrug interactionsefficacygemcitabineirinotecanlactationpermetrexedpregnancysafetytisotumab vedotintopotecanvinorelbine

Substanzen

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunological

Zitieren

APA

(2024). Tisotumab Vedotin (Tivdak) for Cervical Cancer. The Medical Letter on Drugs and Therapeutics, 66(1705), e109-e110. https://doi.org/10.58347/tml.2024.1705g

Vancouver

Tisotumab Vedotin (Tivdak) for Cervical Cancer. The Medical Letter on Drugs and Therapeutics. 2024;66(1705):e109-e110. doi:10.58347/tml.2024.1705g

BibTeX
@article{euvimed2024,
  title = {Tisotumab Vedotin (Tivdak) for Cervical Cancer},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2024},
  volume = {66},
  number = {1705},
  pages = {e109--e110},
  doi = {10.58347/tml.2024.1705g}
}
Kostenlos starten →